AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01359501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
Trial: NCT01418742
Drug: Panitumumab, Doxycycline/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
Trial: NCT01665391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to match active treatment group
Trial: NCT00526175
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
Trial: NCT00146068
Drug: Avonex/Zocor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03395587
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temozolomide, fractionated radiochemotherapy
Trial: NCT00432770
Drug: ARC1779
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03998254
Drug: V503
RxNorm normalized name: POUCH COMFORT PANEL NU-HOPE #EV5033-006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
Trial: NCT00446173
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV Daily Over 4 Hours x 2 Days
Trial: NCT04072887
Drug: QBW251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
Trial: NCT04072887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules administered twice a day for 24 weeks
Trial: NCT04072887
Drug: COPD maintenance background therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide
Trial: NCT03487666
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
Trial: NCT03980756
Drug: AD-206 20mg
RxNorm normalized name: zinc oxide 0.206 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administered before the breakfast during 7 days
Trial: NCT03980756
Drug: AD-206 40mg
RxNorm normalized name: zinc oxide 0.206 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet administered before the breakfast during 7 days
Trial: NCT00864058
Drug: NEURONTIN® 400 mg capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Parke-Davis's marketed product
Trial: NCT00009685
Drug: VRC4302
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04585347
Drug: ALZ-801 205 mg After Food
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01065272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days
Trial: NCT00335153
Drug: Levodopa-carbidopa intestinal gel
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Trial: NCT01417000
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00431743
Drug: Hydroxyethylstarch 130/0,4
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00044915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive 1.25 mg of placebo
Trial: NCT02785068
Drug: nal-IRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan
Trial: NCT02785068
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: folinic acid
Trial: NCT01059136
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
Trial: NCT01023724
Drug: Ketorolac Tromethamine 0.45%
RxNorm normalized name: KETOROLAC TROMETHAMINE 0.45%PF OPH 0.4ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
Trial: NCT01023724
Drug: Bromfenac 0.09%
RxNorm normalized name: Bromfenac 0.09% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
Trial: NCT04085913
Drug: Lidocaine Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincision injection, as is current practice
Trial: NCT04085913
Drug: Bupivacaine Hydrochloride-EPINEPHrine
RxNorm normalized name: Bupivacaine Hydrochloride-Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincision injection
Trial: NCT04085913
Drug: Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
Trial: NCT03521245
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy regimen recommended for breast cancer
Trial: NCT02212886
Drug: GA Depot 80 mg
RxNorm normalized name: methylPREDNISolone acetate 80 MG/ML [DEPO-Medrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment completed
Trial: NCT02212886
Drug: GA Depot 40 mg
RxNorm normalized name: methylPREDNISolone acetate 40 MG/ML [DEPO-Medrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recruitment completed
Trial: NCT00747279
Drug: Intensive insulin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
Trial: NCT00578695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT02317705
Drug: OTL38
RxNorm normalized name: Fluorodeoxyglucose F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02800161
Drug: Maltose
RxNorm normalized name: Maltose
DrugBank: Maltose (DB03323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltose 70g/die
Trial: NCT02258295
Drug: Intragel
RxNorm normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 40 mg in 1 mL TOPICAL LOTION [INTRAL SENSITIVE SKIN ENVIRONMENTAL LIGHTWEIGHT SHIELD BROAD SPECTRUM SPF50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragel has an average molecular weight of 800-1200 kDaltons.
Trial: NCT03385525
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00033111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill manufactured to mimic cabergoline 05mg tablet
Trial: NCT00148876
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 2500 mg/m² orally day 1-14 q day 22
Trial: NCT03981627
Drug: ADO09 formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of ADO09 formulation
Trial: NCT03981627
Drug: NovoRapid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of insulin aspart
Trial: NCT03761810
Drug: S6G5T-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day topical cream
Trial: NCT03761810
Drug: S6G5T-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day topical cream
Trial: NCT02922426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing for 21 consecutive days
Trial: NCT01398748
Drug: Intranasal glutathione - (in)GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
Trial: NCT01398748
Drug: Intranasal glutathione - (in)GSH
RxNorm normalized name: GSH
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
Trial: NCT01398748
Drug: Saline Intranasal Delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administration 1ml 3x/day 12 weeks in 15 participants
Trial: NCT01049620
Drug: RAD001, Capecitabine, Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
Trial: NCT00138775
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03545789
Drug: [18F]MNI-958
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
Trial: NCT03308253
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg tobramycin per patient
Trial: NCT02395614
Drug: triple antibiotic irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket
Trial: NCT03772665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral tablet taken for 24 months
Trial: NCT00811174
Drug: Octagam 10%
RxNorm normalized name: Octagam 10% Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
Trial: NCT01280695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules
Trial: NCT03268941
Drug: TAK-906 Maleate
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-906 Maleate Capsules
Trial: NCT03268941
Drug: Metaclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaclopramide Tablets
Trial: NCT03268941
Drug: TAK-906 Maleate Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-906 placebo-matching Capsules
Trial: NCT02503501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriostatic 0.9% Sodium Chloride
Trial: NCT02127476
Drug: KHK6640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose and multiple ascending doses administration
Trial: NCT02127476
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose and multiple ascending doses administration
Trial: NCT01740401
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
Trial: NCT01455896
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650
Trial: NCT01996124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose, dry inhalation powder, hard capsules via breezhaler
Trial: NCT01886469
Drug: HLD100-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
Trial: NCT00364598
Drug: Anginera, a human tissue replacement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00854139
Drug: Cyclophosphamide, anti-thymocyte globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications
Trial: NCT03788967
Drug: Dummy Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy intravenous infusion.
Trial: NCT01161537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet.
Trial: NCT03788967
Drug: Dummy tablets
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablets orally.
Trial: NCT00321464
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Trial: NCT02602119
Drug: OTL38
RxNorm normalized name: Fluorodeoxyglucose F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of OTL38 prior to surgery
Trial: NCT04039737
Drug: Qingpeng Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
Trial: NCT02245672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via the CRC749 and Diskus devices
Trial: NCT01078363
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of a placebo post heart Transplant for Blood pressure control.
Trial: NCT00138632
Drug: PTK787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visudyne® + PTK787, 500 mg/day
Trial: NCT00138632
Drug: PTK787
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visudyne® + PTK787 1000 mg/day
Trial: NCT00138632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visudyne® + Placebo
Trial: NCT00415922
Drug: ELC200 (carbidopa+levodopa+entacapone)
RxNorm normalized name: carbidopa / entacapone / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03896945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT03350737
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin i.v.
Trial: NCT02688985
Drug: Methyloprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
Trial: NCT03967925
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg prednisolone tapering dose
Trial: NCT04385342
Drug: HP-hMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
Trial: NCT02702180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nebulizer solution for inhalation
Trial: NCT03646474
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
Trial: NCT04321642
Drug: Entonox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entonox gas with mouth piece
Trial: NCT04321642
Drug: Not receive Entonox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receive any gas
Trial: NCT00711971
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control arm
Trial: NCT02768519
Drug: OTS167IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diluted to final concentration with cherry syrup
Trial: NCT01446003
Drug: Placebo for MK-8457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 x 10-mg capsule BID for 10 days
Trial: NCT02632916
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
Trial: NCT00490555
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel 10 g
Trial: NCT01815840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib placebo orally once daily
Trial: NCT01085877
Drug: estradiol, 25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
Trial: NCT01085877
Drug: estradiol, 25 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
Trial: NCT02504580
Drug: HTX-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011 (bupivacaine/meloxicam) by injection.
Trial: NCT02504580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo by injection.
Trial: NCT02504580
Drug: HTX-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-002, by injection or instillation (pooled).
Trial: NCT02504580
Drug: HTX-011A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011A (bupivacaine/meloxicam) by injection.
Trial: NCT02504580
Drug: HTX-011B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
Trial: NCT02504580
Drug: HTX-009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTX-009 by injection and instillation (combination).
Trial: NCT00856544
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet, 5 mg PO BID, 1 year
Trial: NCT00856544
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet, 10 mg PO BID, 1 year
Trial: NCT00856544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film coated tablet, 1 tablet PO BID, 3-6 months
Trial: NCT02435927
Drug: ASLAN001+ CAPOX (Oxaliplatin, capecitabine)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ASLAN001 in combination with oxaliplatin and capecitabine
Trial: NCT01055314
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01055314
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03057561
Drug: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Trial: NCT03057561
Drug: Cardiac MRI with contrast agent, Gadovist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Trial: NCT00568126
Drug: Maca Root
RxNorm normalized name: maca root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g/day of Maca Root for 12 weeks.
Trial: NCT00568126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo provided by research pharmacy daily for 12 weeks.
Trial: NCT00444574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA